Meta-analysis
Apart from two recent studies conducted in 201926 and 202013, all the studies included in the meta-analysis had already been evaluated and reported in the meta-analysis of Mallah et al., 2019.29 The latter found there was no heterogeneity among the studies included in their meta-analysis. In our study, we observed heterogeneity in the macrolide meta-analysis, but not for the macrolide subclasses. Results of the pooled estimates, including the findings for the current study, did not show a significant increased risk of CHD following first trimester use of macrolides, erythromycin, clarithromycin or azithromycin (Figure 3 A - D).